All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The open-label, randomized and controlled study was terminated early however, due to insufficient sample size. Descriptive results were published by Martin Kropff, Department of Haematology at Medizinische Klinik III, Osnabrück, Germany, and colleagues.
The study results for median TTP, ORR and disease progression did not indicate an additional benefit for the use of VCD compared with VD, for the treatment of primary RRMM patients. However, since the proposed sample size was not reached and the study was terminated early, further trials may be required to fully assess the clinical benefit of VCD. The safety profiles of both therapies were relatively similar with VCD showing slightly higher grade ≥3 peripheral neuropathy. The authors commented that the lack of benefit may be due to the use of a low-dose of cyclophosphamide and therefore investigating higher dosing schedules in a VCD combo may be of interest.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox